The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Deinove hands rights to NBTI programme back to Redx Pharma

Thu, 31st Jan 2019 09:45

(Sharecast News) - Drug discovery and development company Redx Pharma announced on Thursday that Deinove had decided not to exercise its option for Redx's 'Novel Bacterial Topoisomerase Inhibitor' (NBTI) programme.The AIM-traded firm said the decision followed a period of nine months of evaluation by Deinove, during which it had sole rights to develop the programme.All rights to the NBTI programme, including all new data generated by Deinove, now reverted to Redx, which said it was exploring options for the programme with other parties with potential interest in licensing the project."Redx entered into an option and license agreement with Deinove for the NBTI programme in March 2018 following a strategic decision to close the Redx anti-infectives unit in 2017, and focus the company on developing new medicines in oncology and fibrosis," the company's board said in its statement."Last week, the company announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has given formal approval to the company to re-commence the phase 1/2a trial for RXC004, an oral porcupine inhibitor targeting the Wnt signalling pathway."Clinical evaluation of RXC004 in patients with advanced solid tumours remains on track to resume in the first half of 2019 following the approval of a revised phase 1/2a clinical trial protocol and drug formulation," the board reported.
More News
5 Nov 2018 12:52

Redx Pharma Showcases Positive Preclinical Trial Results Of RXC004

LONDON (Alliance News) - Redx Pharma PLC on Monday reported a positive data from preclinical studies evaluating RXC004.The results were presented at the National Cancer Research Institute a

Read more
29 Oct 2018 14:50

Redx CEO Lisa Anson elected to Bioindustry Association board

(Sharecast News) - Drug development company Redx Pharma noted an announcement from the UK BioIndustry Association (BIA) on Monday that Lisa Anson had been elected to serve on the BIA board of directors.

Read more
24 Apr 2018 11:17

Redx Pharma Hires AstraZeneca UK President As Chief Executive

LONDON (Alliance News) - Shares jumped in Redx Pharma PLC on Tuesday as it announced the appointment of AstraZeneca PLC executive Lisa Anson as chief executive officer with effect on June in the I

Read more
22 Mar 2018 13:43

Redx Pharma Signs Agreement For Anti-Infective Programme With Deinove

LONDON (Alliance News) - Drug development company Redx Pharma PLC said Thursday that it has signed an option and licence agreement with chemicals company Deinove SAS for Novel

Read more
9 Feb 2017 14:21

RedX Pharma as it proposes discounted capital raising

(ShareCast News) - Shares in RedX Pharma are down almost 5% as it proposes raising £12m, before expenses, via a placing and subscription to advance its drugs pipeline. The proposed placing was of up to 20.5m shares, while the subscription was of 11.5m shares by Lanstead Capital, an institutional inv

Read more
30 Nov 2016 10:13

Redx Pharma To Present Pre-Clinical Profile Of RXC004 At Conference

Read more
20 Oct 2016 11:34

Redx Pharma identifies candidate for inhibitor programme

(ShareCast News) - Drug-development company Redx Pharma has identified a candidate for its reversible Bruton's tyrosine kinase (BTK) inhibitor programme. The compound, named RXC005, has the potential to treat the majority of patients suffering from chronic lymphocytic leukaemia (CLL), including tho

Read more
20 Oct 2016 08:33

Redx Pharma Selects Drug Candidate To Treat Leukaemia

Read more
27 Sep 2016 09:33

WINNERS & LOSERS SUMMARY: Wolseley Sold Amid Job Cuts, No Extra Payout

Read more
19 Sep 2016 08:13

Redx Pharma Sees Cancer Immunotherapy Promise For Porcupine Inhibitor

Read more
11 Sep 2016 15:25

Sunday share tips: Dunelm Group, Green REIT, Redx Pharma

(ShareCast News) - Buy shares in Dunelm Group, said the Sunday Times' Inside the City column. On Wednesday the home furnishings retailer is due to publish its first annual results under new chief executive John Browett. In the final three months of the year the FSTE 250 company - a sort of cut-price

Read more
24 May 2016 09:33

Redx Pharma Loss Widens But Notes Oncology Lead Progress

Read more
19 May 2016 10:17

Redx Pharma Welcomes Paper On Tackling Antimicrobial Resistance

Read more
9 May 2016 07:46

Redx Pharma Appoints David Lawrence Non-Executive Director

Read more
24 Mar 2016 14:08

Redx Pharma Raising GBP10.0 Million To Progress Its Pipeline (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.